ArticleHistology and histopathology2021
Ring finger protein 126: a potential biomarker for colorectal cancer.
Article in Histology and histopathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- KRAS/ERK2-driven stabilization of AARS1 reprograms tumor metabolism and confers Sorafenib resistance in lung adenocarcinoma.Cell death and differentiation · 2026Article
- Review
- SIRT5-RNF126 coordinated regulation of METTL17 stability controls mitochondrial function and glioma progression.Cell & bioscience · 2026Article
- Ubiquitin-proteasome system as a target for anticancer treatment-an update.Archives of pharmacal research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is the most common cancer of the digestive system. However, effective therapeutic targets against CRC have not been found yet. Further, the relationship between the expression of ring finger protein 126 (RNF126) and CRC is not clear. MATERIAL AND
methodsThe expression level of RNF126 in CRC tissues and cell lines was detected by immunohistochemical staining and western blot. Subsequently, endogenous RNF126 expression was inhibited in a CRC cell line using a short hairpin RNA. Next, the effect of RNF126 on the properties of CRC cells was studied through different experimental methods.
resultsWe found that the RNF126 protein was mainly localized in the cytoplasm. High RNF126 expression was observed to be an independent risk factor for poor prognosis in CRC patients. In vitro studies showed that RNF126 was able to promote the proliferation, migration, and invasion ability of CRC cells.
conclusionRNF126 acts as an oncogene during CRC development, and may serve as a novel target for CRC treatment.
Indexed as
Identifiers
33724438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.